BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXW on Nasdaq
Location
3 Rd Floor, Bellevue Centre, 235 15 Th Str, West Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
July 31
Former names
Ansell Capital Corp. (to 6/20/2014)
Latest financial report
10-Q - Q3 2024 - Dec 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 126 % -94.3%
Return On Equity 491 % -21.6%
Return On Assets -191 % -297%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.2M shares +177%
Common Stock, Shares, Outstanding 36.2M shares +126%
Entity Public Float 63.7M USD -39.4%
Common Stock, Value, Issued 82M USD +17.9%
Weighted Average Number of Shares Outstanding, Basic 26.6M shares +66.7%
Weighted Average Number of Shares Outstanding, Diluted 26.6M shares +59.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24M USD +26.7%
General and Administrative Expense 5.99M USD -19.4%
Operating Income (Loss) -30M USD -13.7%
Nonoperating Income (Expense) 94.5K USD -93.5%
Net Income (Loss) Attributable to Parent -16.6M USD -25.8%
Earnings Per Share, Basic -0.89 USD/shares -4.71%
Earnings Per Share, Diluted -0.01 USD/shares +99.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.79M USD -57.6%
Accounts Receivable, after Allowance for Credit Loss, Current 15.2K USD +2.26%
Assets, Current 8.22M USD -55.4%
Property, Plant and Equipment, Net 365K USD
Intangible Assets, Net (Excluding Goodwill) 196K USD
Assets 10.4M USD -44.1%
Liabilities, Current 4.99M USD +377%
Accumulated Other Comprehensive Income (Loss), Net of Tax -139K USD 0%
Retained Earnings (Accumulated Deficit) -91.2M USD -22.2%
Stockholders' Equity Attributable to Parent -3.78M USD -137%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.71M USD +47.6%
Liabilities and Equity 10.4M USD -44.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.96M USD +8.55%
Net Cash Provided by (Used in) Financing Activities 12M USD
Net Cash Provided by (Used in) Investing Activities -75K USD
Common Stock, Shares, Issued 36.2M shares +126%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.93M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.79M USD -57.6%
Deferred Tax Assets, Valuation Allowance 18M USD +13.3%
Deferred Tax Assets, Gross 21.9M USD +37.4%
Depreciation 22.8K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.9M USD +51.1%
Deferred Tax Assets, Operating Loss Carryforwards 5.55M USD +12.8%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 7.92M USD
Depreciation, Depletion and Amortization 3.82K USD +0.03%
Deferred Tax Assets, Net of Valuation Allowance 3.91M USD +8558%
Share-based Payment Arrangement, Expense 392K USD +39.5%